Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PelvEx II study in locally recurrent rectal cancer
NL-OMON54232Phase 3Recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Nov 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine, oxaliplatin, fluorouracil, folinic acid, irinotecan and 1 more in rectal cancer (2 arms), sponsored by Catharina Ziekenhuis. Primary endpoint: R0 resection rate. Started Nov 2020; status: recruiting.
02
Drugs
capecitabineoxaliplatinfluorouracilfolinic acidirinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NL-OMON54232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54232.